CL2013003570A1 - Anticuerpo que se une al ligando-1 de glicoproteina p-selectina (psgl-1); composicion farmaceutica que comprende el anticuerpo anti-psgl-1; kit farmaceutico; dispositivo para inyeccion; y uso del anticuerpo anti psgl-1 o de la composicion que lo contine para preparar un medicamento para tratar un desorden inflamatorio. - Google Patents
Anticuerpo que se une al ligando-1 de glicoproteina p-selectina (psgl-1); composicion farmaceutica que comprende el anticuerpo anti-psgl-1; kit farmaceutico; dispositivo para inyeccion; y uso del anticuerpo anti psgl-1 o de la composicion que lo contine para preparar un medicamento para tratar un desorden inflamatorio.Info
- Publication number
- CL2013003570A1 CL2013003570A1 CL2013003570A CL2013003570A CL2013003570A1 CL 2013003570 A1 CL2013003570 A1 CL 2013003570A1 CL 2013003570 A CL2013003570 A CL 2013003570A CL 2013003570 A CL2013003570 A CL 2013003570A CL 2013003570 A1 CL2013003570 A1 CL 2013003570A1
- Authority
- CL
- Chile
- Prior art keywords
- antibody
- psgl
- composition
- prepare
- treating
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 238000002347 injection Methods 0.000 title abstract 2
- 239000007924 injection Substances 0.000 title abstract 2
- 102000003886 Glycoproteins Human genes 0.000 title 1
- 108090000288 Glycoproteins Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000008212 P-Selectin Human genes 0.000 abstract 1
- 108010035766 P-Selectin Proteins 0.000 abstract 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161496249P | 2011-06-13 | 2011-06-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013003570A1 true CL2013003570A1 (es) | 2014-08-22 |
Family
ID=47357432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013003570A CL2013003570A1 (es) | 2011-06-13 | 2013-12-12 | Anticuerpo que se une al ligando-1 de glicoproteina p-selectina (psgl-1); composicion farmaceutica que comprende el anticuerpo anti-psgl-1; kit farmaceutico; dispositivo para inyeccion; y uso del anticuerpo anti psgl-1 o de la composicion que lo contine para preparar un medicamento para tratar un desorden inflamatorio. |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20130209449A9 (OSRAM) |
| EP (2) | EP2718325A4 (OSRAM) |
| JP (1) | JP6180408B2 (OSRAM) |
| KR (1) | KR102103036B1 (OSRAM) |
| CN (3) | CN108892726A (OSRAM) |
| AU (1) | AU2012271845B2 (OSRAM) |
| BR (1) | BR112013031892A2 (OSRAM) |
| CA (1) | CA2838952C (OSRAM) |
| CL (1) | CL2013003570A1 (OSRAM) |
| CO (1) | CO6940376A2 (OSRAM) |
| EC (1) | ECSP14013132A (OSRAM) |
| IL (2) | IL229844B (OSRAM) |
| MX (1) | MX358447B (OSRAM) |
| NZ (1) | NZ619524A (OSRAM) |
| PH (1) | PH12013502568B1 (OSRAM) |
| RU (1) | RU2650817C2 (OSRAM) |
| SG (1) | SG10201604767TA (OSRAM) |
| TW (1) | TWI643872B (OSRAM) |
| UA (1) | UA114712C2 (OSRAM) |
| WO (1) | WO2012174001A1 (OSRAM) |
| ZA (1) | ZA201400209B (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040116333A1 (en) | 2001-08-03 | 2004-06-17 | Rong-Hwa Lin | Modulators of P-selectin glycoprotein ligand 1 |
| US7744888B2 (en) | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
| MY148646A (en) | 2004-05-10 | 2013-05-15 | Abgenomics Cooperatief Ua | Anti-psgl-1 antibodies |
| AR048840A1 (es) | 2004-05-11 | 2006-05-31 | Boehringer Ingelheim Int | Epitopes inductores de la muerte de las celulas t |
| BR112013031892A2 (pt) | 2011-06-13 | 2016-11-22 | Abgenomics Cooperatief Ua | anticorpos anti-psgl-1 e seu uso |
| CA2953706A1 (en) * | 2014-07-08 | 2016-01-14 | Sanford-Burnham Medical Research Institute | Psgl-1 modulators and uses thereof |
| AU2017206074B2 (en) * | 2016-01-08 | 2023-09-07 | Altrubio Inc. | Tetravalent anti-PSGL-1 antibodies and uses thereof |
| WO2017214941A1 (zh) * | 2016-06-16 | 2017-12-21 | 毛侃琅 | 一种提升SelP基因表达水平的慢病毒载体及其应用 |
| EP3568159A4 (en) | 2017-01-11 | 2020-08-05 | Bristol-Myers Squibb Company | PSGL-1 ANTAGONISTS AND THEIR USES |
| TWI787230B (zh) | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | 抗ＴＧＦ-β抗體及其用途 |
| TW202421659A (zh) * | 2017-01-20 | 2024-06-01 | 美商健臻公司 | 骨靶向抗體 |
| KR20240151866A (ko) | 2017-03-14 | 2024-10-18 | 파이브 프라임 테라퓨틱스, 인크. | 산성 pH에서 VISTA에 결합하는 항체 |
| PE20210290A1 (es) | 2018-03-21 | 2021-02-11 | Five Prime Therapeutics Inc | ANTICUERPOS DE UNION A VISTA A pH ACIDO |
| EP3820902A2 (en) | 2018-07-11 | 2021-05-19 | Five Prime Therapeutics, Inc. | Antibodies binding to vista at acidic ph |
| BR112021000934A2 (pt) | 2018-07-20 | 2021-04-27 | Pierre Fabre Medicament | receptor para vista |
| KR20220042055A (ko) * | 2019-06-04 | 2022-04-04 | 베르조 테라퓨틱스, 아이엔씨. | 골수성 세포 염증성 표현형을 조절하기 위한 항-psgl-1 조성물 및 방법, 그리고 이의 용도 |
| EP4139002A2 (en) * | 2020-05-22 | 2023-03-01 | Formycon AG | Ace2-fc fusion proteins and uses thereof |
| CN113667015B (zh) * | 2021-08-20 | 2022-10-11 | 北京康特泊瑞生物医药科技股份公司 | 靶向psgl-1蛋白的抗体及其用途 |
| KR20240107151A (ko) * | 2021-11-17 | 2024-07-08 | 알트루바이오 인코퍼레이티드 | T-세포 매개 염증 질환 또는 암을 치료하기 위해 jak 억제제와 조합하여 항-psgl-1 항체를 사용하는 방법 |
| WO2024057232A1 (en) * | 2022-09-13 | 2024-03-21 | Tetherex Pharmaceuticals Corporation | Antibodies, compositions, and methods of treatment |
| WO2025106784A1 (en) * | 2023-11-17 | 2025-05-22 | Altrubio Inc. | Anti-psgl-1 antibodies and uses thereof |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| DE3668186D1 (de) | 1985-04-01 | 1990-02-15 | Celltech Ltd | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5378464A (en) | 1989-03-08 | 1995-01-03 | Board Of Regents Of The University Of Oklahoma | Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140 |
| US5464778A (en) | 1989-03-08 | 1995-11-07 | Board Of Regents Of The University Of Oklahoma | Glycoprotein ligand for P-selectin and methods of use thereof |
| US5690933A (en) | 1989-05-31 | 1997-11-25 | Glaxo Wellcome Inc. | Monoclonal antibodies for inducing tolerance |
| US5709859A (en) | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
| US6309639B1 (en) | 1991-02-05 | 2001-10-30 | The Board Of Regents Of The University Of Oklahoma | Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand |
| US6124267A (en) | 1991-02-05 | 2000-09-26 | Southpac Trust Internationals, Inc. | O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1 |
| US5972625A (en) | 1991-05-06 | 1999-10-26 | The Regents Of The University Of California | Assays for inhibitors of leukocyte adhesion |
| EP0640131B1 (en) | 1992-03-17 | 1999-04-21 | Novartis AG | Genetically engineered antibodies |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| US5843707A (en) | 1992-10-23 | 1998-12-01 | Genetics Institute, Inc. | Nucleic acid encoding a novel P-selectin ligand protein |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| US5710123A (en) | 1992-12-18 | 1998-01-20 | Centocor, Inc. | Peptide inhibitors of selectin binding |
| JPH08506017A (ja) | 1993-01-25 | 1996-07-02 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | ドメインの交換によるキメラｌ‐およびｐ‐セレクチン、ならびにそれらの使用 |
| WO1995014787A1 (en) | 1993-11-22 | 1995-06-01 | Centocor, Inc. | Peptide inhibitors of selecting binding |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| CA2228512A1 (en) | 1995-08-03 | 1997-02-20 | The Board Of Regents Of The University Of Oklahoma | Peptide and o-glycan inhibitors of selectin mediated inflammation |
| US6348581B1 (en) | 1996-10-31 | 2002-02-19 | The Dow Chemical Company | High affinity humanized anti-TAG-72 monoclonalantibodies |
| WO1999043353A2 (en) | 1998-02-26 | 1999-09-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination anti-selectin and immunosuppressant therapy |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| JP2002528513A (ja) | 1998-10-30 | 2002-09-03 | ジェネティックス・インスチチュート・インコーポレーテッド | Ｐ−セレクチンリガンド（ｐｓｇｌ）アンタゴニストによる細胞毒性ｔ−細胞分化の阻害 |
| WO2000061739A1 (fr) | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle |
| US6696620B2 (en) | 2000-05-02 | 2004-02-24 | Epicyte Pharmaceutical, Inc. | Immunoglobulin binding protein arrays in eukaryotic cells |
| CA2408883A1 (en) | 2000-05-19 | 2001-11-29 | The Center For Blood Research, Inc. | Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity |
| EP1325123A4 (en) | 2000-09-12 | 2004-07-21 | Inst Genetics Llc | INHIBITION OF STENOSIS OR RESTENOSIS USING P-SELECTINE ANTAGONISTS |
| KR20030091953A (ko) | 2000-12-29 | 2003-12-03 | 사비언트 파마슈티컬즈 인코퍼레이티드 | 황산화된 부분을 함유하는 에피토프를 포함하는 분리된분자, 그러한 에피토프에 대한 항체, 및 그들의 용도 |
| US20040002450A1 (en) | 2000-12-29 | 2004-01-01 | Janette Lazarovits | Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| US20040001839A1 (en) | 2000-12-29 | 2004-01-01 | Avigdor Levanon | Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| CA2385745C (en) | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| US6884619B2 (en) | 2001-07-17 | 2005-04-26 | Yale University | Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors |
| US20040116333A1 (en) | 2001-08-03 | 2004-06-17 | Rong-Hwa Lin | Modulators of P-selectin glycoprotein ligand 1 |
| US7744888B2 (en) | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
| NZ532526A (en) | 2001-10-25 | 2007-01-26 | Genentech Inc | Compositions comprising a glycoprotein having a Fc region |
| JP2005536199A (ja) | 2002-07-01 | 2005-12-02 | サビエント ファーマシューティカルズ，インコーポレイティド | 抗体及びそれらの使用 |
| US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
| KR20060107501A (ko) | 2003-06-30 | 2006-10-13 | 바이오-테크널러지 제너럴 (이스라엘) 리미티드 | 특이적인 인간 항체 |
| TW200540186A (en) * | 2003-12-25 | 2005-12-16 | Kirin Brewery | Mutants of anti-CD40 antibody |
| WO2005080586A1 (en) * | 2004-02-13 | 2005-09-01 | Immunomedics, Inc. | Fusion proteins containing recombinant cytotoxic rnases |
| CA2885854C (en) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| MY148646A (en) | 2004-05-10 | 2013-05-15 | Abgenomics Cooperatief Ua | Anti-psgl-1 antibodies |
| AR048840A1 (es) | 2004-05-11 | 2006-05-31 | Boehringer Ingelheim Int | Epitopes inductores de la muerte de las celulas t |
| US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| TWI309240B (en) * | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| PL2468770T3 (pl) * | 2006-07-14 | 2018-07-31 | Ac Immune S.A. | Humanizowane przeciwciało przeciw amyloidowi beta |
| RS53402B (sr) * | 2007-03-22 | 2014-10-31 | Genentech, Inc. | Vezivanje apoptotskih anti-ige antitela za membranski ige |
| AU2008234248C1 (en) * | 2007-03-29 | 2015-01-22 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| CA2688275A1 (en) * | 2007-05-31 | 2008-12-04 | Genmab A/S | Stable igg4 antibodies |
| EA200901646A1 (ru) | 2007-06-05 | 2010-08-30 | Йел Юниверсити | Ингибиторы рецепторных тирозинкиназ и их применение |
| EP2190480A4 (en) | 2007-08-28 | 2013-01-23 | Biogen Idec Inc | ANTI-IGR-1R ANTIBODIES AND ITS USES |
| JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US8092804B2 (en) * | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| US20110086366A1 (en) * | 2008-02-22 | 2011-04-14 | Genmab A/S | Methods for assessing the risk of adverse events upon treatment with igg4 antibodies |
| EP3388527A1 (en) * | 2008-05-15 | 2018-10-17 | Tetherex Pharmaceuticals Corporation | Anti-psgl-1 antibodies and methods of identification and use |
| WO2010102792A2 (en) * | 2009-03-12 | 2010-09-16 | Imed Ab | Human antibodies against human fas and their use |
| CA2769473A1 (en) | 2009-07-31 | 2011-02-03 | N.V. Organon | Fully human antibodies to btla |
| BR112013031892A2 (pt) | 2011-06-13 | 2016-11-22 | Abgenomics Cooperatief Ua | anticorpos anti-psgl-1 e seu uso |
| EP3157560A4 (en) | 2014-06-20 | 2018-02-21 | Abgenomics International Inc. | Her2 antibody-drug conjugates |
-
2012
- 2012-06-12 BR BR112013031892A patent/BR112013031892A2/pt not_active Application Discontinuation
- 2012-06-12 UA UAA201314798A patent/UA114712C2/uk unknown
- 2012-06-12 WO PCT/US2012/042068 patent/WO2012174001A1/en not_active Ceased
- 2012-06-12 US US13/494,398 patent/US20130209449A9/en not_active Abandoned
- 2012-06-12 AU AU2012271845A patent/AU2012271845B2/en active Active
- 2012-06-12 JP JP2014515918A patent/JP6180408B2/ja active Active
- 2012-06-12 NZ NZ619524A patent/NZ619524A/en unknown
- 2012-06-12 RU RU2013158083A patent/RU2650817C2/ru active
- 2012-06-12 CN CN201810722769.2A patent/CN108892726A/zh active Pending
- 2012-06-12 CN CN201280039482.0A patent/CN103732626A/zh active Pending
- 2012-06-12 SG SG10201604767TA patent/SG10201604767TA/en unknown
- 2012-06-12 CA CA2838952A patent/CA2838952C/en active Active
- 2012-06-12 EP EP12799966.2A patent/EP2718325A4/en not_active Ceased
- 2012-06-12 PH PH1/2013/502568A patent/PH12013502568B1/en unknown
- 2012-06-12 MX MX2013014814A patent/MX358447B/es active IP Right Grant
- 2012-06-12 EP EP21168455.0A patent/EP3925978A1/en active Pending
- 2012-06-12 KR KR1020147000603A patent/KR102103036B1/ko active Active
- 2012-06-12 CN CN202211394154.4A patent/CN116063522A/zh active Pending
- 2012-06-13 TW TW101121146A patent/TWI643872B/zh active
-
2013
- 2013-04-17 US US13/865,085 patent/US20130251708A1/en not_active Abandoned
- 2013-12-08 IL IL229844A patent/IL229844B/en unknown
- 2013-12-12 CL CL2013003570A patent/CL2013003570A1/es unknown
-
2014
- 2014-01-09 ZA ZA2014/00209A patent/ZA201400209B/en unknown
- 2014-01-13 CO CO14004726A patent/CO6940376A2/es unknown
- 2014-01-13 EC ECSP14013132 patent/ECSP14013132A/es unknown
-
2021
- 2021-08-30 US US17/460,883 patent/US11897964B2/en active Active
- 2021-10-14 IL IL287270A patent/IL287270A/en unknown
-
2023
- 2023-12-26 US US18/396,607 patent/US20240124604A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013003570A1 (es) | Anticuerpo que se une al ligando-1 de glicoproteina p-selectina (psgl-1); composicion farmaceutica que comprende el anticuerpo anti-psgl-1; kit farmaceutico; dispositivo para inyeccion; y uso del anticuerpo anti psgl-1 o de la composicion que lo contine para preparar un medicamento para tratar un desorden inflamatorio. | |
| CL2022000328A1 (es) | Anticuerpo humanizado que se une específicamente al receptor de transferrina humano (tfr); composición farmacéutica; uso del anticuerpo humanizado para preparar un medicamento útil para tratar un trastorno neurológico. (divisional solicitud no. 3207-2017) | |
| ES2543174T3 (es) | Composición medicinal para el tratamiento y/o la prevención del cáncer | |
| AR124676A2 (es) | Formulación farmacéutica que comprende una droga biofarmacéutica | |
| CL2016002585A1 (es) | Inmunoconjugado que comprende una proteína de unión a antígeno que se une a antígeno de maduración de linfocitos b (bcma) y un agente citotóxico, composición farmacéutica y su uso (divisional solicitud 201303373) | |
| CL2018000108A1 (es) | Moléculas de anticuerpo que se unen a cd22 | |
| CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
| CL2019002056A1 (es) | Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo o un polipéptido anti leucocidina lukd, lukd aislado o un polipétido del mismo, o una combinación de ambos y portador farmaceuticamente aceptable.(divisional solicitud 201303650) | |
| MX2015011473A (es) | Compuesto de fosforamidato de nucleosido novedoso y su uso. | |
| BR112015022782A2 (pt) | composto, composição farmacêutica, combinação, e, uso de um composto | |
| CL2016000324A1 (es) | Anticuerpos monoclonales que se unen especificamente al inhibidor del activador de plasminogeno de tipo 1 (pai-1); y uso para preparar un medicamento util para restaurar la generación de plasmina o tratar una afeccion causada por el aumento de los niveles de pai-1 o el aumento de la sensibilidad a pai-1. | |
| GT201400111A (es) | Triazolopiridinas sustituidas | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| PE20140004A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y bortezomib | |
| AR087715A1 (es) | Anticuerpos anti pcsk9 y usos de los mismos | |
| CL2012002319A1 (es) | Compuestos derivados de amino-tienopirimidinas que contienen un grupo alquilo sustituido, inhibidores de mnk| o mnk2; composición farmacéutica; y su uso para la profilaxis o la terapia de enfermedades metabólicas, trastornos hematopoyéticos, enfermedades neurodegenerativas, cáncer, entre otras. | |
| MX395149B (es) | Terapias de combinación que comprenden un receptor quimérico de antígeno cd19 para el cáncer. | |
| CL2011000191A1 (es) | Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
| EA201791850A1 (ru) | Борсодержащие малые молекулы | |
| PE20150002A1 (es) | Anticuerpos anti-fcrn | |
| MX373245B (es) | Anticuerpos cd3 humanizados o quiméricos. | |
| PE20140806A1 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| MX374826B (es) | Un anticuerpo biespecífico que se une a pcrv y psl de pseudomonas. | |
| PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
| CL2011000504A1 (es) | Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer. |